martes, 17 de mayo de 2022

Prognostic value of albumin-to-globulin ratio in COVID-19 patients: A systematic review and meta-analysis

Prognostic value of albumin-to-globulin ratio in COVID-19 patients: A systematic review and meta-analysis


Resumen

Background and aims The albumin-to-globulin ratio (AGR) has been used to predict severity and mortality in infectious diseases. The aim of this study is to evaluate the prognostic value of the AGR in COVID-19 patients. Methods A systematic review and meta-analysis were conducted. We included observational studies assessing the association between the AGR values upon hospital admission and severity or all-cause mortality in COVID-19 patients. In the meta-analyses we used random effect models. Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). The effect measures were expressed as mean difference (MD) and their 95% confidence intervals (CI). We performed Egger's test and funnel plots to assess the publication bias. Results The included studies had a total of 11356 patients corresponding to 31 cohort studies. Severe COVID-19 patients had lower AGR values than non-severe COVID-19 patients (mean difference (MD), −0.27; 95% IC, −0.32 to −0.22; p < 0.001; I2 = 88%). Non-survivor patients with COVID-19 had lower AGR values than survivor patients (MD, −0.29; 95% IC, −0.35 to −0.24; p < 0.001; I2 = 79%). In the sensitivity analysis, we only included studies with low risk of bias, which decreased the heterogeneity for both outcomes (severity, I2 = 20%; mortality, I2 = 5%). Conclusions Low AGR values upon hospital admission were found in COVID-19 patients with a worse prognosis.

NOMBRE DE LA REVISTA

Heliyon

BASE DE DATOS A LA CUAL PERTENECE

Scopus, Pubmed, Web of Science, Embase

TIPO DE MANUSCRITO

Revisión sistemática y meta-análisis

IDIOMA

Inglés 

AUTORES DE LA SOCIEDAD 

Enrique A. Hernandez-Bustamante

LEER ARTÍCULO COMPLETO

viernes, 6 de mayo de 2022

Eficacia de la colchicina en el tratamiento de pacientes con COVID-19: una revisión sistemática y un metanálisis

Eficacia de la colchicina en el tratamiento de pacientes con COVID-19: una revisión sistemática y un metanálisis

 



Resumen

Objective: We assessed the efficacy of colchicine in COVID-19 patients through a systematic review. Methods: Six databases were searched until March 2022 for studies assessing colchicine versus control in hospitalized patients with COVID-19. The primary outcome was mortality, and secondary outcome was length of hospitalization. Inverse variance and random effect meta-analyses were performed. The strength of evidence was assessed using GRADE. Results: Nine studies (five randomized clinical trials (RCTs) and four non-randomized studies of intervention (NRSI); n = 13,478). Colchicine did not reduce mortality in comparison with the standard of care in RCTs (RR 0.99; 95%CI 0.90 to 1.10; p = 0.90); however, it did reduce mortality in NRSI studies (RR 0.45; 95%CI 0.26 to 0.77; p = 0.02). In the analysis of RCTs, colchicine did not reduce the length of hospitalization in comparison with the standard of care (MD: −2.25 days; 95%CI: −9.34 to 4.84; p = 0.15). Most studies were scored as having a high risk of bias. Quality of evidence was very low for primary and secondary outcomes. Conclusion: Colchicine did not reduce the mortality and length of hospitalization in comparison with the standard of care in hospitalized patients with COVID-19. The published evidence is insufficient and of very low quality to recommend treatment in patients with COVID-19.

TITLE

Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis

NOMBRE DE LA REVISTA

Journal of Clinical Medicine

BASE DE DATOS A LA CUAL PERTENECE

Scopus, SCIE, PubMed, PMC, Embase, CAPlus

TIPO DE MANUSCRITO

Revisión sistemática y metanálisis

IDIOMA

English 

AUTORES DE LA SOCIEDAD 

Jerry K. Benites Meza

LEER ARTÍCULO COMPLETO